Penny stocks to consider buying while their prices are this cheap

Some of the penny stocks I’ve been watching have already climbed above the 100p level. But I see potential in a number of others.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Whenever I search for potential penny stocks to buy, one small pharmaceutical firm keeps popping up.

It’s Poolbeg Pharma (LSE: POLB), and it has a novel research model that’s light on cash, and offers the potential to develop multiple product lines at lower costs than traditional methods.

There’s artificial intelligence (AI) in there, and I find that both exciting and cause for concern. The potential for AI is huge, but any stock that merely mentions it seems to get a boost.

Poolbeg shares have been climbing since late 2022. But we’re still looking at a market cap of only £62m.

There’s no sign of profit yet, and that has to be the biggest risk. But when I look at a company with promising technology and that is valued so lowly, I see the cost of a takeover at just pocket money for a big pharma giant.

Even in terms of specific research products, the company talks about possible sales of the whole production at an early stage.

If I went for Poolbeg, it might be in the hope of a future buyout from a big company… and it would only be with a small amount of cash.

Lithium please

The Kodal Minerals (LSE: KOD) share price is only 0.44p. But it was as low as 0.27p in February, so that’s a gain of more than 60% already.

To be fair, it did briefly peak at nearly a full penny in early 2023. But that’s when a lithium stock boom was on, and it’s well down since then.

With a market cap of £89m, Kodal isn’t far under the usual limit for UK penny stocks of £100m.

The main risk is the lack of current profits. But analysts are tentatively forecasting modest positive earnings by 2026.

After its recent funding round, Kodal reported £11.2m in cash on the books. So its lithium development plans don’t seem to be under any financial threat right now.

Still, until we see profit, and know the extent of any shareholder dilution before we get there, there’s still a fair bit of risk.

Not a penny stock

I’m going to cheat now, and make a third pick. This one, Michelmersh Brick Holdings (LSE: MBH), is not quite a penny stock any more at 105p. But it was less than £1 very recently, and the market cap is still below the £100m mark.

For me, the investment case here is straightforward. We have profits, with forecast rising earnings. And there’s a forward dividend yield of 4.3%, expected to grow to 4.7% by 2027.

And that’s from a small-cap company with price-to-earnings (P/E) multiples that look set to drop below 10.

With its last FY results, the firm spoke of maintaining a well-balanced forward order book, after a decline in the market, and remaining resilient as it awaits new growth.

A lot depends on a UK property market and housebuilding recovery. And that could take longer than bullish investors like me might think. But it’s another possible long-term buy for me.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

Just released: our top 3 small-cap stocks to consider buying in October [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

How I’d use an empty Stocks and Shares ISA to aim for a £1,000 monthly passive income

Here's how using a Stocks and Shares ISA really could help those of us who plan to invest for an…

Read more »

Investing Articles

This FTSE stock is up 20% and set for its best day ever! Time to buy?

This Fool takes a look at the half-year results from Burberry (LON:BRBY) to see if the struggling FTSE stock might…

Read more »

Investing Articles

This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

As the WH Smith share price falls 4% on annual results, is it still worth considering?

WH Smith took a hit after this morning’s results left shareholders unimpressed. With the share price down 4%, Mark Hartley…

Read more »

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »